Physician profile
Thuy Le
NPI 1255869970
$1,852.34
in general payments reported to CMS, 2019-2025
19 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $378 · 2023: $333 · 2024: $614 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381 · Education: $92.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.29 |
| Education | $92.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $344.17 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $205.23 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $162.18 | 2023-2025 | Lupkynis |
| Travere Therapeutics, INC. | $143.49 | 2023-2025 | Filspari |
| Daiichi Sankyo INC. | $134.42 | 2024-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $125.00 | 2022 | |
| Nxstage Medical, INC. | $120.00 | 2022 | |
| Ardelyx, INC. | $98.90 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $68.41 | 2023-2025 | Farxiga |
| Opko Pharmaceuticals, LLC | $60.89 | 2023 | Rayaldee |
| Lilly USA, LLC | $57.45 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.45 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $52.15 | 2022-2023 | Krystexxa |
| Amgen INC. | $50.70 | 2024-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $47.63 | 2023-2024 | Jynarque |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $44.29 | 2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $39.46 | 2022-2024 | Velphoro |
| Genzyme Corporation | $23.69 | 2022 | |
| Vifor Pharma, INC. | $17.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.